Welcome and Introduction
Johann Gudjonsson, MD, PhD, United States
The Microbiome and Psoriasis
Wilson Liao, MD, United States
TCR Analysis Using Genomics Data
Emanual Maverakis, MD, United States
Statistical Genomics and Multi-omic Approaches in Advancing Genetic Research for Psoriasis
Alex Tsoi, MS, PhD, United States
Towards Personalized Diagnosis and Therapy
Curdin Conrad, MD, Switzerland
Panel Discussion
All Faculty
Introduction to Poster Presentations
Alex Tsoi, MS, PhD, United States
Granzyme K Promotes IL-23 Secretion and Keratinocyte Proliferation in Psoriasis
Katlyn Richardson – University of British Columbia, Canada
Prevalence and Association of Psoriasis in Patients with Seborrheic Dermatitis: A Systematic Review and Meta-Analysis
Christy Chang – University of Illinois at Chicago, United States
Comparing Itch in Psoriasis, Atopic Dermatitis, and Chronic Idiopathic Urticaria: A Meta-Analysis
Julia L. Gao, MD – Beth Israel Deaconess Medical Center, United States
Periodontitis as a Risk Factor for Psoriasis
Rudolf E. Schopf, MD – Johannes Gutenberg University, Germany
Heterogeneity of Psoriatic Skin Lesions Identified by a Novel Transcriptomic Based Psoriasis Cell and Immune Score
Sneha Shrotri – Ampel Biosolutions, United States
Dual Role of Dermal Adipogenesis in Regulating Neutrophil Activation and Regression
Ling-Juan Zhang, PhD – Xiamen University, China
Comparative Whole Metagenome Sequencing Analysis in Psoriasis Capitis Patients and Healthy Individuals
Britta De Pessemier – Ghent University, Belgium
Comparative Multiomics Study of Inflammatory Skin Diseases Uncover Novel Disease-Specific Heterogeneity in Skin Resident Myeloid Cells
Mehdi Rashighi, MD – University of Massachusetts – Chan Medical School, United States
Closing and Adjourn
Johann Gudjonsson, MD, PhD, United States
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.
